Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines

Cellular Oncology

Volumn 35, Issue 4, 2012, Pages 243-257

  Koch, Annemarie ^a   Hatina, Jiri ^a,b   Rieder, Harald ^c   Seifert, Hans Helge ^a,d   Huckenbeck, Wolfgang ^e   Jankowiak, Frank ^c   Florl, Andrea R ^a   Stoehr, Robert ^f   Schulz, Wolfgang A ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Heinrich Heine Universitadie t   (Germany)

^d Hegau Bodensee Klinikum   (Germany)

^e Institut für Rechtsmedizin   (Germany)

^f UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

133 isoform; Bladder cancer; FGFR3; P53 alternative promoter; Papillary urothelial carcinoma; Rs17878362 intronic polymorphism

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA POLYMERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE CA; PROTEIN P53; UNCLASSIFIED DRUG;

ALLELE; ANEUPLOIDY; CANCER CELL; CANCER CELL CULTURE; CLINICAL ARTICLE; CYTOPLASM; EXON; GENE DELETION; GENE EXPRESSION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INTRON; KARYOTYPING; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RNA SPLICING; UROGENITAL TRACT CANCER; WESTERN BLOTTING;

ALTERNATIVE SPLICING; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY, NUCLEIC ACID; SPECTRAL KARYOTYPING; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84870027169     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0082-8     Document Type: Review

References (37)

1. J.I. Epstein, Diagnosis and classification of flat, papillary, and invasive urothelial carcinoma: the WHO/ISUP consensus. Int. J. Surg. Pathol. 18, 106S-111S (2010)
2. W.A. Schulz, Understanding urothelial carcinoma through cancer pathways. Int. J. Cancer 119, 1513-1518 (2006) (Pubitemid 44258755)
3. G. Niegisch, A. Koch, J. Knievel, W.A. Schulz, P. Albers, Signal transduction in urothelial cancer : How exactly do we know the targets for targeted therapy?. Urologe A (2010)
4. P.J. Goebell, M.A. Knowles, Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol. Oncol. 28, 409-428 (2010)
5. H.H. Seifert, A. Meyer, M.V. Cronauer, J. Hatina, M. Muller, H. Rieder, M.J. Hoffmann, R. Ackermann, W.A. Schulz, A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder. World J Urol. 25, 297-302 (2007)
6. M.P. Williamson, P.A. Elder, M.A. Knowles, The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer 9, 108-118 (1994) (Pubitemid 24047466)
7. M. Hollstein, P. Hainaut, Massively regulated genes: the example of TP53. J. Pathol. 220, 164-173 (2010)
8. R.U. Jänicke, V. Graupner, W. Budach, F. Essmann, The do's and don'ts of p53 isoforms. Biol. Chem. 390, 951-963 (2009)
9. V. Olivares-Illana, R. Fahraeus, p53 isoforms gain functions. Oncogene 29, 5113-5119 (2010)
10. R. Saldana-Meyer, F. Recillas-Targa, Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics 6 (2011)
11. M.P. Khoury, J.C. Bourdon, p53 isoforms: an intracellular microprocessor? Genes Cancer. 2, 453-465 (2011)
12. R. Holmila, C. Fouquet, J. Cadranel, G. Zalcman, T. Soussi, Splice mutations in the p53 gene: case report and review of the literature. Hum. Mutat. 21, 101-102 (2003)
13. V. Marcel, S. Perrier, M. Aoubala, S. Ageorges, M.J. Groves, A. Diot, K. Fernandes, S. Tauro, J.C. Bourdon, Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett. (2010)
14. K.P. Magnusson, M. Sandstrom, M. Stahlberg, M. Larsson, J. Flygare, D. Hellgren, K.G. Wiman, S. Ljungquist, p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. Gene 246, 247-254 (2000) (Pubitemid 30190178)
15. G. Hofstetter, A. Berger, H. Fiegl, N. Slade, A. Zoric, B. Holzer, E. Schuster, V.J. Mobus, D. Reimer, G. Daxenbichler, C. Marth, A.G. Zeimet, N. Concin, R. Zeillinger, Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene 29, 1997-2004 (2010)
16. J. Southgate, K.A. Hutton, D.F. Thomas, L.K. Trejdosiewicz, Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest. 71, 583-594 (1994) (Pubitemid 24338167)
17. M.J. Hoffmann, W.A. Schulz, Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 83, 296-321 (2005) (Pubitemid 41297199)
18. A.R. Florl, K.H. Franke, D. Niederacher, C.D. Gerharz, H.H. Seifert, W.A. Schulz, DNA methylation and the mechanisms of CDKN2A inactivation in transitional cell carcinoma of the urinary bladder. Lab Invest. 80, 1513-1522 (2000)
19. W. Otto, S. Denzinger, S. Bertz, A. Gaumann, P.J. Wild, A. Hartmann, R. Stoehr, No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. Int. J. Cancer 125, 2205-2208 (2009)
20. B. Vojtesek, H. Dolezalova, L. Lauerova, M. Svitakova, P. Havlis, J. Kovarik, C.A. Midgley, D.P. Lane, Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10, 389-393 (1995)
21. E. Schrock, S. du Manoir, T. Veldman, B. Schoell, J. Wienberg, M.A. Ferguson-Smith, Y. Ning, D.H. Ledbetter, I. Bar-Am, D. Soenksen, Y. Garini, T. Ried, Multicolor spectral karyotyping of human chromosomes. Science 273, 494-497 (1996) (Pubitemid 26286449)
22. A.R. Brothman, D.L. Persons, L.G. Shaffer, Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res. 127, 1-4 (2009)
23. B. Hiller, J. Bradtke, H. Balz, H. Rieder, CyDAS: a cytogenetic data analysis system. Bioinformatics 21, 1282-1283 (2005) (Pubitemid 40467962)
24. T. Yeager, W. Stadler, C. Belair, J. Puthenveettil, O. Olopade, C. Reznikoff, Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 55, 493-497 (1995)
25. E.J. Chapman, C.D. Hurst, E. Pitt, P. Chambers, J.S. Aveyard, M.A. Knowles, Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene 25, 5037-5045 (2006)
26. E.J. Chapman, G. Kelly, M.A. Knowles, Genes involved in differentiation, stem cell renewal, and tumorigenesis are modulated in telomerase-immortalized human urothelial cells. Mol. Cancer Res. 6, 1154-1168 (2008)
27. N.J. MacLaine, M.D. Wood, J.C. Holder, R.W. Rees, J. Southgate, Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol. Cancer Res. 6, 53-63 (2008) (Pubitemid 351378166)
28. B. George, R.H. Datar, L. Wu, J. Cai, N. Patten, S.J. Beil, S. Groshen, J. Stein, D. Skinner, P.A. Jones, R.J. Cote, p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J. Clin. Oncol. 25, 5352-5358 (2007) (Pubitemid 350232209)
29. P.J. Goebell, S.G. Groshen, B.J. Schmitz-Drager, p53 immunohistochemistry in bladder cancer -a new approach to an old question. Urol. Oncol. 28, 377-388 (2010)
30. M.P. Khoury, J.C. Bourdon, The isoforms of the p53 protein. Cold Spring Harb. Perspect. Biol. 2, a000927 (2010)
31. V. Marcel, V. Vijayakumar, L. Fernandez-Cuesta, H. Hafsi, C. Sagne, A. Hautefeuille, M. Olivier, P. Hainaut, p53 regulates the transcription of its Delta133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene 29, 2691-2700 (2010)
32. K. Fujita, A.M. Mondal, I. Horikawa, G.H. Nguyen, K. Kumamoto, J.J. Sohn, E.D. Bowman, E.A. Mathe, A.J. Schetter, S.R. Pine, H. Ji, B. Vojtesek, J.C. Bourdon, D.P. Lane, C.C. Harris, p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat. Cell Biol. 11, 1135-1142 (2009)
33. J. Chen, S.M. Ng, C. Chang, Z. Zhang, J.C. Bourdon, D.P. Lane, J. Peng, p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev. 23, 278-290 (2009)
34. Y. Ye, H. Yang, H.B. Grossman, C. Dinney, X. Wu, J. Gu, Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 112, 2467-2474 (2008)
35. J.P. Melis, E.M. Hoogervorst, C.T. van Oostrom, E. Zwart, T.M. Breit, J.L. Pennings, A. de Vries, H. van Steeg, Genotoxic exposure: novel cause of selection for a functional DeltaN-p53 isoform. Oncogene 30, 1764-1772 (2011)
36. Z. Hu, X. Li, R. Yuan, B.Z. Ring, L. Su, Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res. Treat. 120, 705-714 (2010)
37. C. Varley, G. Hill, S. Pellegrin, N.J. Shaw, P.J. Selby, L.K. Trejdosiewicz, J. Southgate, Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp. Cell Res. 306, 216-229 (2005) (Pubitemid 40692785)